From the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. (X.J.W., H.M.).
Ann Intern Med. 2018 Nov 6;169(9):ITC65-ITC80. doi: 10.7326/AITC201811060.
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. Most cases are diagnosed incidentally in the primary care or hospital setting on the basis of elevated liver enzyme levels or hepatic steatosis on imaging. NAFLD encompasses a wide spectrum: The vast majority of patients have nonprogressive nonalcoholic fatty liver, and a few of those develop progressive liver injury, inflammation, and fibrosis, a condition termed nonalcoholic steatohepatitis. Cardiovascular disease is the leading cause of death in patients with nonalcoholic fatty liver disease. Persons with nonalcoholic steatohepatitis have increased liver-related mortality. In the absence of regulatory agency-approved drugs, lifestyle modification and weight loss remain the cornerstones of NAFLD therapy.
非酒精性脂肪性肝病(NAFLD)是慢性肝病的主要原因。大多数病例是在初级保健或医院环境中偶然发现的,其依据是肝酶水平升高或影像学检查显示肝脂肪变性。NAFLD 涵盖了广泛的范围:绝大多数患者为非进展性非酒精性脂肪肝,其中少数患者进展为进行性肝损伤、炎症和纤维化,这种情况称为非酒精性脂肪性肝炎。心血管疾病是非酒精性脂肪性肝病患者死亡的主要原因。患有非酒精性脂肪性肝炎的人肝脏相关死亡率增加。在没有监管机构批准的药物的情况下,生活方式改变和减肥仍然是非酒精性脂肪性肝病治疗的基石。